Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | KDM5C | P41229 | 1/20 | 0.53 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.52 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | PDE9A | O76083 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14442482 | 0.89 | KDM5A (0.64) | KDM5AKDM5CKDM5BPDE10ADHODH | |
| SCHEMBL14607233 | 0.80 | PDE9A (0.57) | PDE9APARP1 | |
| SCHEMBL4753505 | 0.78 | KDM5A (0.57) | KDM5AKDM5CKDM5BPDE10ADHODH | |
| SCHEMBL22871658 | 0.73 | KDM5A (0.75) | KDM5AKDM5CKDM5BPDE10APDE9A | |
| SCHEMBL4754631 | 0.70 | KDM5A (0.69) | KDM5AKDM5CKDM5BPDE10ADHODH | |
| SCHEMBL20870262 | 0.70 | KDM5A (1.00) | KDM5AKDM5CKDM5BPDE9APARP1 | |
| SCHEMBL22298103 | 0.70 | KDM5A (0.69) | KDM5AKDM5CKDM5BPDE10APDE9A | |
| SCHEMBL23885638 | 0.68 | PDE10A (0.50) | KDM5AKDM5CKDM5BPDE10ADHODH | |
| SCHEMBL14441620 | 0.68 | HSD11B1 (0.36) | KDM5AKDM5CKDM5BPDE10APDE9A | |
| SCHEMBL10134606 | 0.67 | PARP1 (0.79) | KDM5AKDM5CKDM5BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | MIF, MSR1, SLC11A2 | KDM5A 3709/4885KDM5C 4271/4885KDM5B 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.